Get started
Author

Olfa Derbel

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
2022 · François-Clément Bidard, Anne-Claire Hardy-Bessard, et al. · The Lancet Oncology · 381
Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and exhaustive population-based cohort)
2017 · Olfa Derbel, Pierre Etienne Heudel, et al. · PLoS ONE · 91
PDF
Results of combined treatment of anaplastic thyroid carcinoma (ATC)
2011 · Olfa Derbel, Sami Limem, et al. · BMC Cancer · 90
PDF
Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience
2013 · Alice Levard, Olfa Derbel, et al. · BMC Cancer · 82
PDF
Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
2013 · Jean-Yves Blay, Antoine Italiano, et al. · BMC Cancer · 77
PDF
Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer
2017 · S. Intidhar Labidi-Galy, Timothée Olivier, et al. · Clinical Cancer Research · 59
Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma
2015 · Olivia Bally, Louis Tassy, et al. · Clinical Sarcoma Research · 57
PDF
Giant-cell tumor of bone, anti-RANKL therapy
2012 · Armelle Dufresne, Olfa Derbel, et al. · BoneKEy Reports · 40
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial
2024 · Isabelle L. Ray-Coquard, Aude-Marie Savoye, et al. · Nature Communications · 32
Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers
2019 · S. Intidhar Labidi-Galy, Thibault de La Motte Rouge, et al. · Gynecologic Oncology · 29
Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14)
2019 · Frédérique Penault-Llorca, Fabrice Kwiatkowski, et al. · The Breast · 28
PDF
Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery
2013 · Olfa Derbel, Qing Wang, et al. · BMC Cancer · 28
PDF
An Unusual Giant Cell Tumor of the Thyroid: Case Report and Review of the Literature
2012 · O. Derbel, P. Zrounba, et al. · The Journal of Clinical Endocrinology & Metabolism · 25
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma
2024 · Olivia Le Saux, Maude Ardin, et al. · Nature Communications · 22
Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme
2019 · Romain Varnier, Olivia Le Saux, et al. · European Journal of Cancer · 18
PDF
Adhesion to Clinical Practices Guidelines (CPG'S) and Role on Survival for Soft Tissue Sarcoma Patients. Analysis of a Population Based Cohort from Rhone-Alpes Region
2012 · O. Derbel, C. Cropet, et al. · Annals of Oncology · 15
Efficacy and safety results from neopembrov study, a randomized phase II trial of neoadjuvant chemotherapy (CT) with or without pembrolizumab (P) followed by interval debulking surgery and standard systemic therapy ± P for advanced high-grade serous carcinoma (HGSC): A GINECO study.
2021 · Isabelle Laure Ray-Coquard, Aude Marie Savoye, et al. · Journal of Clinical Oncology · 13
Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study
2015 · Christelle de la Fouchardiere, Nadia Oussaid, et al. · Targeted Oncology · 10
The clinician’s perspective on sarcoma pathology reporting: impact on treatment decisions?
2013 · Jean-Yves Blay, Olfa Derbel, et al. · Pathology · 8
Sorafenib and sunitinib for elderly patients with renal cell carcinoma
2013 · Olfa Derbel Miled, Christine Dionne, et al. · Journal of Geriatric Oncology · 8
179O Combination of olaparib, durvalumab and fulvestrant in patients with advanced ER-positive, HER2-negative breast cancer harboring homologous recombination repair (HRR) deficiency or microsatellite instability (MSI): Results of the international phase II DOLAF trial
2024 · S. Guiu, J. Balmaña, et al. · ESMO Open · 7
Location of mutation in BRCA2 gene and survival in patients with ovarian cancer
2017 · S.I. Labidi-Galy, T. Olivier, et al. · Annals of Oncology · 7
Concomitant Occurrence of Pulmonary Invasive Aspergillosis and Pneumocystis Pneumonia During FOLFIRINOX Chemotherapy for Pancreatic Carcinoma
2012 · Julien Péron, Olfa Derbel, et al. · Pancreas · 7
Unusual Adverse Event With Vandetanib in Metastatic Medullary Thyroid Cancer
2011 · Sophie Duplomb, Amandine Benoit, et al. · Journal of Clinical Oncology · 7
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe)
2024 · Florence Joly, Fernando Bazan, et al. · JNCI Cancer Spectrum · 5
PDF
Works count: 81
Citation count: 1,566
H-index: 16
I10-index: 19
Year
Topic
Type